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Abstract
The burden of cancer in old age is increasing as a result from both the expanding number of older persons in the
population and the high and still increasing cancer incidence in this group. The goal of this article is to outline the
shortcomings and challenges of the management of cancer in the elderly. Several factors contribute to the complexity of this
management, such as the enormous heterogeneity in this population, increased co-morbidity, reduced functional status,
increased frailty and different treatment goals from those in younger patients. Other problems include the lack of data on the
efficacy and toxicity of cancer treatment in this age group, the lack of awareness of life-expectancy and the lack of an easy
applicable and validated frailty scale. Improvement of the quality of oncological care in this age group could be achieved by
initiation of clinical trials specifically directed at the elderly, in which a frailty scale is implemented. The results of these
trials may lead to more evidence-based decision making in cancer treatment in the elderly. Ó 2001 Elsevier Science B.V.
All rights reserved.
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Currently over 60% of newly diagnosed cancers persons, the magnitude of the cancer burden in the
occur in patients over 65 years of age [1]. aged is clear. Survival data from 17 European
This percentage is increasing as earlier in this countries demonstrated that elderly with cancer face
decade 55% of all malignancies were identified in a worse prognosis than younger patients [3]. This
this group, while about 20 years ago it was only 50% inferior prognosis may be the product of several
[1]. Tumour registry data obtained in 1997 by the factors, such as differences in biological behaviour
nine comprehensive cancer centres in our country of the tumour, decreased DNA-repair and age-related
established that cancer is most common in the host factors as hormone receptors and circulating
elderly, as 28% of new patients was aged between 65 hormone levels, and mostly these cannot be affected
and 74 years and 30% was 75 years or older [2]. [4]. However, as least as important are the observed
Combined with a still expanding number of older age-related differences in diagnostic procedures and
therapy [5–8], upon which still is room for improve-
ment. These age-related differences derive from both
*Corresponding author. Tel.: 1 31-50-361-6161; fax: 1 31-50- patient- and doctor-related factors. Examples of361-4862.
patient-related factors are co-morbidity, co-medica-E-mail address: a.n.m.wymenga@int.azg.nl (A.N.M.
Wymenga). tion, ethnicity, educational level, cognitive status,
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access to transportation, social support and the diagnostic procedures are performed. Some of these
results of physiological decline, whereas doctor-re- are patient-related while others are doctor-related
lated factors include attitude, know-how, assump- [11,12].
tions, generalizations and prejudice. Because of this, Examples of patient-related factors are ignorance
the pro’s and cons for diagnostic procedures and of (non-specific) symptoms or attributing them to
treatment options in older patients are not always normal ageing or to co-morbid conditions. Other
properly balanced. About 10–15% of the elderly factors are the assumption that cancer is contagious,
experience an optimal ageing without occurrence of or the overwhelming idea that cancer is not a
co-morbidity (‘old and fit’). When cancer is diag- treatable disease.
nosed in a person within this group, the calendar age Examples of doctor-related factors are the lack of
should not be an argument in therapeutic decisions, knowledge of the normal proces of ageing and of
and the first choice in oncological care should be the life-expectancy, stereotyped opinions, and therapeu-
prevailing standard treatment. However, in frail older tic nihilism. All these factors also contribute to
patients counter-arguments about treatment can be referral filters, of which the exact magnitude and
considerable, and decisions regarding treatment underlying mechanisms still have to be unraveled.
should be weighed carefully. In this article we Older patients are probably less frequently referred
outline our view with respect to optimal oncological to tertiary cancer centres, while differences in diag-
care for older patients. Specific issues on medical nostic and therapeutic approach between tertiary
treatment such as alterations in pharmaco-dynamics cancer centres and general hospitals are very likely.
or pharmacokinetics are beyond the scope of this In a retrospective study of ovarian cancer patients,
review. differences were observed in background and ex-
perience of surgeons: in the patient group over 80
years old, only 14% were treated by a gyneacologic
Diagnostic procedures and filters for referral oncologist, 29% by an obstetrician /gynaecologist
and 31% by a general surgeon [13]. These figures
The basis of adequate oncological care comprises were 23, 56 and 14%, respectively for patients under
careful diagnostic examinations followed by suffi- 60 years. Another illustration of the existence and
cient staging procedures, as stage governs both influence of referral filters are the results of a study
treatment and prognosis. However, in older patients comparing performance status and co-morbidity in
the diagnostic work-up is often less extensive com- older cancer patients ( . 70 years), younger cancer
pared to their younger counterparts, so that there is a patients ( , 70 years) and non-cancer patients [14].
higher proportion of unstaged disease in the elderly Older cancer patients intriguingly exhibited a better
[5]. It can be assumed that there is a similar functional status and less co-morbidity than older
difference in diagnostic approaches in the preceding patients with non-neoplastic disease. In this study the
phase in which a histological diagnosis has not been selection of patients probably influenced the results
obtained. An essential key in diagnosing a disease is as the cancer patients were recruited from specialised
a thorough physical examination. Although older cancer centres, whereas the non-cancer patients were
patients visit a doctor more frequently than younger recruited from geriatric or general medicine depart-
patients, and consequently undergo more often a ments. In our country referral filters have been found
general physical examination, the number of too. The variation in referral for postoperative
gynecological examinations declines [9]. This could radiotherapy for endometrial carcinoma stage I was
be the result of the misperception that older patients mainly determined by differences in opinion between
might reject such examinations. In a survey regard- referring gynaecologists [15]. In prostate cancer
ing the attitude of doctors and of older patients patients, the decision of urologists to use radical
towards rectal examinations, the majority of patients prostatectomy was not only determined by patients’
considered it an important examination and did not age and tumour characteristics, but also by the type
find it disagreeable [10]. The literature suggests of hospital in terms of case-load [16].
several reasons why in older patients less intensive The management of older patients with cancer
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varies between countries. Differences in incidence as specifically aimed at older cancer patients, who have
well as percentage of histologically verified cancer been underrepresented in common cancer trials. For
between neighbouring countries do not reflect example, the overall accrual in the South-West
genuine differences but have to be attributed to Oncology Group trials between 1993 and 1996 for
dissimilar management. If survival data are consid- patients 65 years of older was only 25%, whereas the
ered as endpoint for management, the lower survival corresponding proportion of cancer in the general
for elderly, as well as younger patients, in Eastern population in this age group was 63% [19].
European countries compared to other European As well as age restrictions related to inclusion
countries, probably reflects the difference in access criteria, other reasons elucidated for this underrepre-
to and quality of care [3]. The various management sentation are the exclusion due to co-morbidity,
of cancer in old age not only results from disparity in advanced stage of disease, lower level of education,
economical resources but also from another cultural the idea that older patients have less benefit from
point of view. For example, the concept of ‘Tenju- aggressive treatment, the lack of financial, social,
Gann’ or ‘natural end cancer’ has recently been and logistic support for participation in a trial as well
advocated [17]. Tenju-gann is derived from the as low referral [20,21]. Considering this underrepre-
Japanese words ‘ten’ which means heaven and ‘ju’ sentation of older patients, the interpretation of these
which means ‘celebrated long life’ and considers the trials needs to be viewed with caution, because a
development of cancer at very old ages as more or selection bias, including only the ‘best’ elderly,
less inevitable. Sometimes the result may be a likely influences the results.
peaceful death with minimal suffering. This concept,
probably more accepted in non-Western countries,
rejects aggressive treatment, but may also preclude Life-expectancy
appropriate diagnostic procedures and therefore
causes surrogate decisions [17,18]. During the last century, life-expectancy has gradu-
In our opinion, a proper approach to each older ally increased. For the Dutch population, the mean
patient starts with a complete evaluation of the life-expectancy for a male septagunarian is 11 years,
symptoms and signs, which have to be clarified for an octogenerian 6 years, and for a nonagenerian
satisfactory, and in which the occurence of a malig- it is still 3 years. For females these figures are even
nancy always has to be considered. Referrals to more impressive, 15, 8 and 4 years, respectively
medical specialists have to accomplished if neces- [21]. Against this, the variability of the life-expec-
sary. After the diagnosis of cancer has been con- tancy is increased, which decreases confidence of
firmed histologically, or is thought to be very likely, individual predictions. The heterogeneity within the
complementary diagnostic procedures are only war- older population, usually defined as everyone aged
ranted when there are therapeutic consequences. over 65 years, partly results from the wide age range.
These therapeutic consequences, chemotherapy, In addition, the age at which patients are considered
surgery, radiotherapy, were recently reviewed by ‘elderly’ varies in the literature. In geriatric medicine
Turner et al. [7]. Those therapeutic consequences are often the limit of 65 years is mentioned, whereas in
determined by the life-expectancy, contra-indications the European literature on cancer in the elderly often
if any, as well as by the patients’ acceptance of the the age limit of 70 years is used. Some authors
treatment proposed. advocate to distinguish the ‘young old’ (65–74
years), the ‘older old’ (75–84 years) and the ‘oldest
old’ (85 years or older) [1]. Subdivision in age
Lack of data groups is primarily important for research purposes,
which secondarily can influence individual treatment
A major obstacle in selecting the optimal cancer decisions. For example, after comparison of clinical
treatment for older patients is the lack of sound data and histological characteristics and outcome of
on the efficacy and toxicity of therapy, as well as on Dutch Non-Hodgkin lymphoma patients, patients
quality of life. This is because few studies are with indolent lymphoma are considered ‘elderly’
The Netherlands Journal of Medicine 2001;59:259 –266
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when they are older than 70 years whereas in conditions with increasing age was observed in
aggressive lymphoma this occurs when patients are colorectal and prostate cancer patients in our country
older than 65 years [22]. The life-expectancy is [16,26]. The assessment of co-morbidity is important
crucial in decisions regarding oncological treatment. for decisions regarding treatment and the expected
For example, in a 90-year-old person suffering from toxicity profile, but has also implications for prog-
a bowel obstruction due to a sigmoid tumour, a nosis. The number of co-morbidities were predictive
surgical resection will be performed as the profit and of early mortality in colon- and breast cancer
loss account will in the short term go in favour of [27,28]. In breast cancer patients suffering from three
profit. However, when the histological examination or more concomitant diseases the all cause mortality
reveals a Dukes-C colon carcinoma, no adjuvant appeared 4-fold higher than in the patients without
chemotherapy will be proposed because any benefit comorbid conditions [28]. In Dutch colorectal cancer
manifests after several years [23]. patients, co-morbidity did not affect the resection
rate but did negatively influence short-term survival
[26].
Co-morbidity A consequence of the enhanced co-morbidity is
the accompanying, often abundantly provided, co-
Next to life-expectancy, co-morbidity deserves medication. A cross-sectional study in three general
attention. In the Netherlands, the increase in life- practices in the Netherlands showed that one third of
expectancy observed between 1983 and 1994 is all patients aged over 65 years used two ore more
mainly based on an increase of ‘unhealthy years’, drugs [29]. This polypharmacy can lead to drug
although the severity of this ‘ill health’ declined interactions interfering with cytotoxic agents, and
[21]. The rise in unhealthy life-expectancy particu- therefore should be considered in terms of treatment
larly is related to the corresponding increase in decisions.
age-dependent diseases, whose pathogenesis directly
involves normal ageing [24]. Examples are cardio-
vascular diseases, osteoporosis and Alzheimers’ dis- Functional status
ease. The incidence and prevalence of these age-
dependent diseases gradually increase with ageing, Ageing is often associated with a decline in
and in many cases the transition between physiologi- functional status, which refers to the ability to
cal ageing and age-dependent disease is ill-defined. perform tasks, and includes basic activities of daily
They form a major part of co-morbidity and strongly life (BADL) such as eating, bathing, dressing and
influence life-expectancy, quality of life and frailty movement but also more complex activities such as
as well as decisions regarding treatment. using the telephone, shopping, housekeeping, hand-
Tumour registry data for 7600 cancer patients in ling finances (instrumental activities of daily life,
the United States showed in patients aged between IADL). In a Danish cross sectional study, the phys-
55–64, 65–74 and over 75 an increase in the mean ical abilities evaluated by changes in activities of
number of co-morbidities from 2.9 to 3.6 and 4.2 [1]. BADL gradually inclined with ageing without level-
In contrast, the number of patients without any co- ling off [30]. Functional limitations, low physical
morbidity declined in these groups from about 10 to activity as well as cognitive impairment have been
6% and 4%, respectively. In a Dutch series of 3864 identified as risk factors for receiving inadequate
lung cancer patients, the prevalence of co-morbidity treatment for cancer [31]. Cancer in itself is associ-
was higher in patients aged over 70 years (69%) ated with impairment in BADL and IADL, but these
compared with patients aged below 70 years (52%) reductions are less important than the limitations
[25]. The most frequent concomitant diseases were observed in other chronic conditions such as is-
cardiovascular (23%), chronic obstructive pulmonary chaemic heart disease, chronic pulmonary disease
disease (22%), other malignancies (15%), hyperten- and rheumatoid arthritis [32].
sion (12%) and diabetes mellitus (7%). A compar- Functional status should be evaluated accurately
able increasing prevalence of relevant comorbid for several reasons. First, in oncological trials func-
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tional status is often assessed by the Karnofsky score ised patients [37]. Rockwood et al. reported a dose–
or the ECOG performance score, which are known response curve between frailty and institutionalisa-
for their predictive value for outcome. However, tion as well as survival with their frailty scale, which
these quite crude scales probably underrate func- probably under-rates psychosocial issues [43].
tional impairment in older persons. Second, physical In geriatric oncology often the frailty definition
functioning prior to the diagnosis appeared to be a according to Balducci is used (Table 1) [44].
predictor of physical functioning during and after This definition is for rapid screening very helpful,
treatment in geriatric cancer patients [33]. Last, although a few comments can be made. In our
physicians underestimate the functional disabilities opinion, age over 85 years should be considered
and psychological problems of their patients [34,35]. more as a risk factor for frailty than as an absolute
criteria. Prospective data using this frailty scale in
cancer patients are not yet available, although some
of the items proved predictors of survival. The frailty
Frailty definition does not include a grading of the severity
of frailty, which could be helpful for individual
In geriatrics, the judgment of the ‘general con- treatment decisions.
dition’, considering multiple domains prevails. For these reasons, an easy applicable, validated
Frailty is a metaphysical notion implying this assessment of frailty is urgently required. After
‘general condition’. The frailty concept is an umbrel- implementation in clinical trials, this assessment
la, covering multiple domains, such as co-morbidity, could guide decisions regarding anti-cancer treat-
functional and sensory impairment, incontinence, ment. In case of recording a frailty score below a
mobility, falls, nutrition, cognitive functioning, psy- certain level A, treatment will be beneficial and
chological factors and social support [36–38]. Until coincide with acceptable toxicity, while in case of a
now, no agreement has been accomplished about the frailty score above a certain level B, treatment will
ultimate definition of frailty. Moreover, a valid be unwise. In case of a frailty score between A and
assessment of frailty is still lacking. B, treatment can be considered, but intensive suppor-
Co-morbidity and functional status are important tive care measures have to be taken.
determinants in cancer treatment with respect to Besides the prediction of efficacy and toxicity, this
efficacy, toxicity and survival, as discussed above. brief frailty assessment could even be a predictor of
Previously, they appeared independent variables in survival. The frailty value could be evaluated regu-
older cancer patients, and should be measured separ- larly, because several determinants can be influenced
ately [39]. by interventions, such as nutrition.
However, one might question whether the the
Karnofsky or WHO-scales used in oncological re-
search for functional status are sensitive enough for
Table 1
use in older patients. In addition, co-morbidity and Frailty (according to Balducci): the presence of any of these
functional status comprise only two domains and a criteria establishes frailty
more comprehensive multi-domain evaluation is Age 85 years and older
advocated [40,41]. This comprehensive screening ADL Dependence in one or more
however, is time-consuming and seems not always Comorbidity One or more
Geriatric Syndromes One or morenecessary. An alternative would be the ‘Multidimen-
Deliriumsional Assessment for Cancer in the Elderly’ primari-
Dementialy designed for oncological-geriatric research [42]. Depression
In the past, simple clinical screening instruments Osteoporosis
of frailty appeared useful in case-finding as well as Incontinence
Fallsin predicting outcome [37,43]. Frailty appeared to be
Neglect and abusemore predictive of mortality and nursing home
Failure to thrive
utilization than age or diagnostic groups in hospital-
The Netherlands Journal of Medicine 2001;59:259 –266
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Acceptance of therapy cant changes do not always correspond with clinical-
ly relevant changes [53]. There is still a lack of large
A noteworthy aspect of care for older cancer databases enclosing normal values for ‘healthy’
patients is their acceptance of the treatment pro- persons, different age groups and certain patient
posed. In several studies age-related differences populations [53]. The subjective grading of ex-
concerning the profit and loss account of treatment perienced changes in quality of life is not constant.
have been demonstrated. Older patients did not differ Cultural factors influence quality of life and especial-
from younger patients in acceptance of agressive ly in multicentre studies this might confuse results
chemotherapy aiming either cure or palliation, but [54]. Generally, symptom relief is highly valued and
were less willing to accept toxicity (with negative is usually associated with improvement of quality of
impact on quality of life) for survival time [45]. life [55]. In optimal oncological care, the quality of
Bremmes et al. [46] sketched a hypothetical situation life at presentation and the patients’ expectations and
to untreated cancer patients at their first admission desires about their lives have to be elucidated before
for receiving chemotherapy. ‘‘You have been re- treatment is started and probably even before far
ferred to our oncological unit for treatment of a reaching examinations have been arranged. In case
malignant tumour. The treatment is toxic and has of abandoning anti-tumour therapy, adequate pallia-
numerous side-effects and drawbacks’’. tive care should be provided. Paralleling differences
Patients under 40 years would accept this toxic in cancer treatment, differences in palliative care
treatment with hardly any benefit such as the reduc- between age groups have been recognized, in which
tion of symptoms (8%), life prolongation (3 months) older patients often come off badly compared to
and chance of cure (7%). In contrast, patients older younger patients [6,56].
than 60 years accepted this treatment only for a 50%
chance of reduction of symptoms, a life prolongation
of 12 months and a chance of cure of 50%. When a Future perspectives
comparable hypothetical case was proposed to lung
cancer patients who previously received chemother- The issue of oncological care in old age is
apy, again a difference in minimal survival threshold extensive and complex, and requires more attention
for acceptance of treatment was established, namely and education of health care staff [7]. Oncologists
4.5 months for patients younger than 60 years and 9 should be aware of the pros and cons of cancer
months for patients older than 70 years [47]. In this treatment, which in turn should be assessed by
study, also a choice was given between chemo- validated instruments. It is to be hoped that a frailty-
therapy and supportive care. Remarkably, only 22% indicator will be developed, which can be im-
of all patients chose chemotherapy, in the group of plemented in oncological research.
patients younger than 60 years 65% chose supportive Challenges for research comprise studies directed
care and in the patients older than 70 years this specifically at older patients. In these studies, geriat-
percentage increased to 85%. These kind of studies ric and frailty assessments should be taken along
have not only been performed in settings using with quality of life as a primary endpoint. This
chemotherapy. Among 148 patients with prostate should provide grounds for treatment decisions, and
cancer 26% preferred surveillance over surgery even lead to evidence-based geronto-oncology. However,
when there was a small 10-years benefit of surgery because of the enormous heterogeneity in the older
[48]. population, the evidence achieved will not unequivo-
Fortunately quality of life assessments receive cally correspond with the best treatment for the
increasing attention. Frequently used and validated individual patient. Patients will still require some
scales are the EORTC QLQ-C30, the FACT scale individual balancing of treatment options.
and the Rotterdam symptom check list [49–52]. Leading on from the fact that oncological care to,
However, the interpretation of data obtained by only a few, children is provided by special peadiatric
surveys of quality of life need some consideration oncologists, we advocate the emergence of special
and pitfalls can be recognized. Statistically signifi- geronto-oncologists, in the first instance for academ-
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and comorbidity in elderly cancer patients compared withic centres. These geronto-oncologists should not only
young patients with neoplasia and elderly patients withoutprovide care to older cancer patients but also play an
neoplastic conditions. Cancer 1998;82:760–5.important role in clinical research and education of
¨[15] Lybeert MLM, van Putten WLJ, Brolmann HAM, Coebergh
oncologists in referring centres and community based JWW. Postoperative radiotherapy for endometrial carcinoma
physicians. This may lead to tailored oncological stage I. Wide variation in referral patterns but no effect on
long-term survival in a retrospective study in the Southeastcare for older persons, so that the lamentation from
Netherlands. Eur J Cancer 1998;34:586–90.the Lancet in 1990 ‘‘Cancer in the elderly, why so
[16] Post PN, Kil PJM, Hendrikx AJM, Janssen-Heijnen MLG,badly treated’’ [57] can be definitely abandoned in Crommelin MA, Coebergh JWW. Comorbidity in patients
the new century. with prostate cancer and its relevance in treatment choice. Br
J Urol 1999;84:652–6.
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